Shares of Sun Pharma, Ranbaxy fall as HC fails to give nod on merger

Posted By:
Subscribe to GoodReturns

 Shares of Sun Pharma, Ranbaxy fall as HC fails to give nod on merger
Sun Pharmaceutical Industries: Quotes, News
BSE 515.80BSE Quote0.8 (0.16%)
NSE 518.00NSE Quote2.2 (0.42%)
Shares in Sun Pharma and Ranbaxy both fell after the Andhra Pradesh High Court asked stock exchanges not to approve the deal, until it decides on the insider trading petition.

The stock of Sun Pharma was down 1.3 per cent, while Ranbaxy dropped 2 per cent in trade. A writ petition has been filed by a group of investors alleging that entities with prior knowledge of the deal profited from the deal. The allegations were based on the belief that the Ranbaxy stock rose sharply ahead of the deal.

Sun Pharma had earlier this month said that they would acquire Ranbaxy Laboratories in an all stock deal which would create India's largest pharma company and the world's 5th largest specialty generic pharma company.
Under the agreement, Ranbaxy shareholders would receive 0.8 share of Sun Pharma for each share of Ranbaxy. This exchange ratio represented an implied value of Rs 457 for each Ranbaxy share.
The proposed transaction was unanimously approved by the Boards of Directors of SunPharma, Ranbaxy, and Ranbaxy's controlling shareholder, Daiichi Sankyo. Ranbaxy's board and Sun Pharma's board have recommended approval of the transaction to their respective shareholders.

Read more on the deal here

Today's decision is being termed correct in view of the fact the Ranbaxy stock had rallied, ahead of the announcement, indicating that there may have been insider trading in the stock.

Read more about: sun pharma, ranbaxy
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'